The subscription period for Diamyd Medical's rights issue runs from April 15 to April 29, 2025. It is also possible to subscribe for units without preferential rights. Allotment of units for subscriptions without preferential rights will be made in accordance with the principles set out in the EU growth prospectus that has been published. Interested investors are encouraged to contact their bank or nominee to participate in the issue. In the event that the respective bank or nominee has closed the opportunity to subscribe for units without preferential rights before the end of the subscription period, interested investors are advised to contact the issuer agent, Aqurat Fondkommission, for further information.

The rights issue is covered by subscription commitments and subscription intentions amounting to approximately SEK 47.4 million, corresponding to approximately 22.8 percent of the rights issue.

Diamyd Medical's CEO, Ulf Hannelius, will present at G&W Småbolagsfrukost on Wednesday, April 23, 2025, at 10:00 AM. The presentation will take place at Studio Valo, Västra Trädgårdsgatan 19 in Stockholm. Registration for the event can be made via the following link (the event will also be broadcast via the same link):
https://g-w-smabolagsfrukost.events.inderes.com/april-2025

The prospectus
The prospectus, together with all other information pertaining to the rights issue, is held available on the Company's website, www.diamyd.com, as well as on Aqurat Fondkommission's website, www.aqurat.se. The prospectus will also be made available on the Swedish Financial Supervisory Authority's website, www.fi.se.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the rights issue. Aqurat Fondkommission AB has been appointed as Issuer Agent.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd^® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd^® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd^® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. An early read-out of the Phase 3 trial is expected in March 2026. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group - both in a largescale meta-analysis as well as in the Company's prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.